Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TCR T-cell Therapy for Advanced GI Malignancies
NCT06690281Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of KRAS T-cell receptor-transduced peripheral blood lymphocytes + TP53 T-cell receptor-transduced peripheral blood lymphocytes in gastrointestinal carcinoma, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), sponsored by National Cancer Institute. Planned start Sep 2025; status: withdrawn.
02
Drugs
KRAS T-cell receptor-transduced peripheral blood lymphocytes + TP53 T-cell receptor-transduced peripheral blood lymphocytes
03
Conditions
gastrointestinal carcinomapancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06690281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690281.